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ABSTRACT 
Colorectal cancer (CRC) is a heterogeneous disease that is caused by the interaction of genetic and environmental 
factors. Although it is one of the most common cancers worldwide, CRC would be one of the most curable cancers 
if it is detected in the early stages. Molecular changes that occur in colorectal cancer may be categorized into three 
main groups: 1) Chromosomal Instability (CIN), 2) Microsatellite Instability (MSI), and 3) CpG Island Methylator 
phenotype (CIMP). Microsatellites, also known as Short Tandem Repeats (STRs) are small (1-6 base pairs) re-
peating stretches of DNA scattered throughout the entire genome and account for approximately 3 % of the human 
genome. Due to their repeated structure, microsatellites are prone to high mutation rate. Microsatellite instability 
(MSI) is a unique molecular alteration and hyper-mutable phenotype, which is the result of a defective DNA 
mismatch repair (MMR) system, and can be defined as the presence of alternate sized repetitive DNA sequences 
which are not present in the corresponding germ line DNA. The presence of MSI is found in sporadic colon, 
gastric, sporadic endometrial and the majority of other cancers. Approximately, 15-20 % of colorectal cancers 
display MSI. Determination of MSI status in CRC has prognostic and therapeutic implications. As well, detecting 
MSI is used diagnostically for tumor detection and classification. For these reasons, microsatellite instability anal-
ysis is becoming more and more important in colorectal cancer patients. The objective of this review is to provide 
the comprehensive summary of the update knowledge of colorectal cancer classification and diagnostic features 
of microsatellite instability. 
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INTRODUCTION 
Colorectal cancer (CRC) is the third most 
prevalent cancer in humans and the third most 
common cause of cancer related deaths in 
both males and females that contributes to a 
significant public health problem worldwide 
(Siegel et al., 2012; Jemal et al., 2011). The 
majority of colorectal cancer cases are spo-
radic (about 75 %) that display no apparent 
evidence of having inherited disorders, sug-
gesting contribution of genetic and environ-
mental factors, whereas only 25 % of the pa-
tients have family histories of the disease 
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(Jasperson et al., 2010). Only 5-6 % of pa-
tients with colorectal cancer with a family 
background are due to inherited mutations in 
major CRC genes, while the rest are the result 
of accumulation of both genetic mutations 
and epigenetic modifications of several genes 
(Migliore et al., 2011). According to the cur-
rent knowledge, CRC mainly develops 
through a gradual accumulation of genetic 
and epigenetic alterations of the genome 
(Fearon and Vogelstein, 1990). Molecular 
changes that occur in colorectal cancer may 
be categorized into three main groups: 1) 
Chromosomal Instability (CIN), 2) Microsat-
ellite Instability (MSI), and 3) CpG Island 
Methylator phenotype (CIMP) that silences 
gene function with aberrant hypermethylation 
(Worthley and Leggett, 2010). CIN-positive 
CRCs are featured with alterations in the 
structure and number of chromosome besides 
increased mutation rates in both tumor sup-
pressor genes and oncogenes. Actually, muta-
tion rates in single nucleotides are higher in 
MSI-positive CRCs than in CIN-positive 
CRCs (Cancer Genome Atlas Network, 
2012). On the other hand, 15-20 % of CRCs 
display MSI caused by defective DNA mis-
match repair (MMR) system (Vilar and 
Gruber, 2010). In this review, we provide the 
comprehensive summary of the current 
knowledge in the field of colorectal cancer 
classification and diagnostic features of mi-
crosatellite instability. 
 
TYPES OF CRC AND THEIR  
GENETIC BASIS 
According to etiology and genetics of the 
disease, CRC is usually classified into three 
distinct groups: sporadic, familial, and hered-
itary (Table 1) (Sameer, 2013). 
 
Sporadic CRC 
Sporadic colorectal cancer is the most 
common type of CRC and includes approxi-
mately 75 % of cases that display no apparent 
evidence of having inheritance of disorder. 
However, this is unclear, since genetic factors 
seem to affect the likelihood of cancer even in 
the absence of specific mutations. Sporadic 
colorectal cancer is common among elder 
people, probably as a result of environmental 
factors, dietary, and aging (Arvelo et al., 
2015). MSI-H sporadic colorectal cancers 
are the most often (about 70 %-95 %) caused 
 
 
Table 1: Types of colorectal cancer and their genes 
Types of CRC  Genes involvement  Chromosomal locus Inheritance 
pattern 
Sporadic APC  5q22.2 Non-inherited 
K-RAS  12p12.1 
DCC  18q21.2 
P53  17p13.1 
COX-2  2p14.1 
BCL-2  18q21.33 
related MMR genes   
etc.  
Familial  Unknown  --- Non-inherited 
Hereditary    
FAP  APC  5q22.2 AD 
MAP  MUTYH  1p34.1 AR 
PJS  STK11/ LKB1  19p13.3 AD 
SPS  Unknown  --- --- 
LS  MLH1 
MSH2 
MSH6 
PMS2 
 
 
 
 
3p22.2 
2p21-p16.3 
2p16.3 
7p22.1 
AD 
CRC: colorectal cancer, FAP: Familial adenomatous polyposis, MAP: MUTYH-associated polyposis, PJS: Peutz-Jeghers syn-
drome, SPS: Serrated polyposis syndrome, LS: Lynch syndrome, AD: Autosomal Dominant, AR: Autosomal Recessive 
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by alteration of MLH1 gene via somatic pro-
motor hypermethylation (Copija et al., 
2017). 
 
Familial type of CRC 
This type of CRC is often considered spo-
radic and not any associated gene has been 
identified yet. People with a history of colo-
rectal cancer in a first-degree relative are at 
increased risk of two to three times higher 
than the normal population (Lin, 2012). 
 
Hereditary type of CRC 
The hereditary type of CRC is divided into 
five subtypes: 
 
Familial adenomatous polyposis (FAP) 
Familial adenomatous polyposis is the 
most common hereditary polyposis syn-
drome, which is an autosomal dominant dis-
ease caused by a mutation in the APC gene on 
chromosome 5q21. The APC gene is a tumor 
suppressor gene that produces APC protein, a 
multifunction protein which controls how 
quickly cells grow and prevent the develop-
ment of tumors. The normal function of APC 
protein is the regulation of β-catenin by its 
degradation. β-catenin plays an important role 
in cell communication, Wnt signalling path-
way, and growth by acting as a transcription 
factor for proliferation genes. Mutations in 
the APC gene lead to loss of APC function 
and result in an accumulation of β-catenin. 
Many different mutations (e.g. insertions, de-
letions, nonsense mutations) of the APC gene 
are described as a cause of FAP (Bogaert and 
Prenen, 2014). In addition to APC mutation, 
other mutations, such as K-RAS, DCC, P53, 
COX-2, BCL-2 and etc. are required to de-
velop cancer (Zeichner et al., 2012). In FAP 
patients, polyps are mainly found in the prox-
imal colon and rarely in the rectum. The aver-
age age for people with FAP to develop 
polyps is 35 years and if FAP is not recog-
nized and treated, most likely it will develop 
colorectal cancer (Laurent et al., 2011). There 
are four subtypes of FAP that are caused by 
different germ line mutations in the APC 
gene: Attenuated FAP (AFAP), Gardner syn-
drome, Turcot syndrome, and Gastric Adeno-
carcinoma and Proximal Polyposis of the 
Stomach (GAPPS). 
 
MUTYH-associated polyposis (MAP) 
MUTYH-associated polyposis is one of 
the hereditary polyposis syndromes which is 
an autosomal recessive disease and is caused 
by a biallelic germline mutation in MUTYH 
gene on chromosome 1p34.1. MUTYH gene 
encodes an enzyme called MYH glycosylase 
that is involved in a DNA repair system called 
Base Excision Repair (BER). The number of 
polyps in MAP disease is less than FAP and it 
is phenotypically similar to attenuated FAP 
(Goodenberger and Lindor, 2011). The aver-
age age for diagnosis of MAP is between 40-
60 years old and if MAP is not recognized and 
treated, patients will have an 80 % risk of de-
veloping CRC (Theodoratou et al., 2010). The 
majority of studied CRCs in people with 
MAP were microsatellite stable; although the 
MSI-H (high-level microsatellite instability) 
phenotype is reported in the minority of CRCs 
of persons with MAP (Nielsen et al., 2011; 
Castillejo et al., 2014).  
 
Peutz-Jeghers syndrome (PJS) 
Peutz-Jeghers syndrome is a rare autoso-
mal dominant disorder, which is one of the 
hereditary polyposis syndromes and is char-
acterized by multiple benign hamartomatous 
polyps in the gastrointestinal tract, most often 
found in the small intestine. The number of 
polyps in PJS is less than MAP syndrome and 
those polyps are present from childhood (Gi-
ardiello and Trimbath, 2006). The major 
cause of this disease is germ line mutations in 
the STK11 (serine threonine kinase 11) gene, 
also known as the LKB1, which is a tumor 
suppressor gene and is located on chromo-
some 19p13.3 (Chae and Jeon, 2014). Muta-
tions in this gene change the structure and/or 
function of the STK11 protein, disrupting its 
ability to restrain cell division with the loss of 
kinase activity. Microsatellite instability, 
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LOH nearby the APC gene, and KRAS muta-
tions have been identified in some tumors 
(Shah and Lindor, 2010). 
 
Serrated polyposis syndrome (SPS) 
Serrated polyposis syndrome is a rela-
tively rare syndrome characterized by multi-
ple serrated polyps of the colon, which was 
previously known as the hyperplastic polypo-
sis syndrome (Sweetser et al., 2013). This 
syndrome is usually considered sporadic and 
underlying genetic causes are related to 
germline mutations of oncogene-induced se-
nescence pathway genes (Gala et al., 2014). 
These tumors will be more often considered 
MSI-low or MSS (Microsatellite Stable) 
(Guarinos et al., 2012). There are three crite-
ria for diagnosis of SPS and an individual 
would be considered affected if have at least 
one of them; A) at least five serrated polyps 
proximal to sigmoid with at least two of them 
being greater than 1 cm; B) Any number of 
serrated polyps occurring proximal to the sig-
moid colon in an individual who has a first-
degree relative with SPS; and C) more than 20 
serrated polyps distributed throughout the co-
lon. Furthermore, it would be noteworthy to 
indicate that SPS has been associated with an 
increased risk of developing CRC considering 
previous studies (Rex et al., 2012). 
 
Lynch syndrome (LS) 
Lynch syndrome (LS), also was known as 
Hereditary non-polyposis colorectal cancer, is 
the most common hereditary colon cancer 
syndrome which is an autosomal dominant 
disease and is caused by germline mutations 
in one of several DNA mismatch repair 
(MMR) genes, including MSH2 on chromo-
some 2p16, MLH1 on chromosome 3p21, 
MSH6 on chromosome 2p16, and PSM2 on 
chromosome 7p22 (Lynch et al., 2009). 
MSH2 and MLH1 mutations account for the 
majority of Lynch syndrome cases (Lynch 
and Shaw, 2013). MMR genes encode pro-
teins that are critical to the suitable repair of 
DNA sequence mismatch and correct base 
mismatches or small deletions or insertions 
(Shi and Washington, 2012). Inactivation of 
these genes interrupts DNA repair and causes 
an alteration in the short-tandem DNA repeti-
tive sequences or microsatellites, resulting in 
the development of a phenotype known as mi-
crosatellite instability which is a hallmark of 
Lynch syndrome. This syndrome is account-
ing for approximately 2-3 % of the total CRC 
cases (Hampel et al., 2005). High-level mi-
crosatellite instability is observed in approxi-
mately 90 % of LS-associated CRCs (Boland 
and Shike, 2010). 
 
CONSENSUS MOLECULAR SUB-
TYPES OF CRC 
To resolve inconsistencies between CRC 
classifications based on gene expressions re-
ported and simplify clinical translation four 
Consensus Molecular Subtypes (CMSs) with 
distinct features have been reported. The 
CMS1 are (microsatellite instability immune, 
14 %), hypermutated, microsatellite unstable 
and are immunogenic. The CMS2 are (canon-
ical, 37 %), epithelial, marked WNT and 
MYC signalling activation and have the high-
est overall survival. The CMS3 are (meta-
bolic, 13 %), epithelial and evident metabolic 
cancer phenotype; and the CMS4 (mesenchy-
mal, 23 %), prominent transforming growth 
factor–β activation, stromal invasion and an-
giogenesis that have a worst survival. The 
Consensus Molecular Subtypes of CRC with 
clear biological interpretability may have a 
better prognosis, therapeutic response, and 
potential new treatment strategies (Guinney et 
al., 2015; Thanki et al., 2017). 
 
MOLECULAR BASIS OF DNA  
MISMATCH REPAIR SYSTEM 
DNA mismatch repair system (MMR) 
corrects erroneous insertion, deletion, and 
base-base mismatches generated during DNA 
replication and recombination that have es-
caped the proofreading process (Jiricny, 
2006). This repair pathway is highly con-
served from bacteria to humans and safe-
guards the integrity of the genome (Hsieh and 
Yamane, 2008). MutS and MutL are the main 
proteins involved in prokaryote MMR system 
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that function as homodimers whereas, in eu-
karyotes, MSH2, MSH3, and MSH6 are hom-
ologs for MutS; MLH1, MLH2, MLH3 are 
MutL homologs. There are also other homo-
logs for MutL (post-meiotic segregation) 
named PMS1 and PMS2 which interact as 
heterodimers (Fukui, 2010). When a mis-
match is detected in the eukaryotic genome, 
DNA mismatch repair system functions 
through a series of steps: MSH2 associates 
with MSH6 or MSH3 causing the formation 
of MutSα and MutSβ heterodimers, respec-
tively. MutSα recognizes single base mis-
matches and small insertion/deletion loops 
(IDLs), while MutSβ recognizes larger loops. 
MutSα or MutSβ can recruit MutLα, MutLβ 
or MutLγ heterodimers (if MLH1 couples 
with PMS2, PMS1 or MLH3, respectively) by 
means of exchanging adenosine triphosphate 
(ATP) to adenosine diphosphate (ADP). This 
complex (MutS-MutL) creates a sliding 
clamp around the DNA. The proteins in slid-
ing clamp interact with exonuclease-1 and 
proliferating cell nuclear antigen (PCNA). 
This complex excises the daughter strand 
back to the site of the mismatch. Finally, re-
synthesize and re-ligation are performed by 
DNA polymerase and DNA ligase, respec-
tively. The correction occurs (Figure 1) (Li, 
2008; Martín-López and Fishel, 2013). 
 
MICROSATELLITE INSTABILITY 
(MSI) 
Microsatellites, also known as Short Tan-
dem Repeats (STRs) are small (1-6 base 
pairs) repeating stretches of DNA scattered 
throughout the entire genome (both in coding 
and non-coding regions) and account for ap-
proximately 3 % of the human genome. Due 
to their repeated structure, microsatellites are 
prone to high mutation rate (Ellegren, 2004). 
Microsatellite instability in tumor DNA is de-
fined as the presence of alternate sized repet-
itive DNA sequences that are not present in 
the corresponding germline DNA. Microsat-
ellite instability (MSI) is a molecular pheno-
type due to a defective DNA mismatch repair 
system.  
The presence of MSI is found in the spo-
radic colon, gastric, sporadic endometrial and 
the majority of other cancers (Yamamoto and 
Imai, 2015). Determination of MSI status in 
CRC has prognostic and therapeutic implica-
tions. As well, MSI can be used diagnostically 
for tumor detection and classification (Setaffy 
and Langner, 2015). MSI has always been as-
sociated with an improved prognosis, stage 
for stage. Recently the reason for this has 
been discovered, a reason that has changed 
our approach to advanced MSI-high disease. 
The unstable microsatellites are highly immu-
nogenic, so that therapy that activates the im-
mune system can have almost miraculous ef-
fects on unstable tumors. This has led to pro-
posals to develop tumor vaccines and to turn 
MSS tumors into MSI to make them more im-
munogenic. 
 
DETECTION OF MSI 
MSI is detected indirectly by analysis of 
MMR protein expression by Immunohisto-
chemical (IHC) staining, or directly by PCR-
based amplification of specific microsatellite 
repeats, which is the most common method to 
detect MSI (Buecher et al., 2013).  
 
IHC method 
Immunohistochemical analysis can deter-
mine loss of expression of one or more of 
MMR proteins. Actually, IHC is correlates 
with MSI but it is not a perfect test for MSI 
determination. It is a test of expression of mis-
match repair proteins in cells. In this method, 
antibodies against MMR proteins such as 
MLH1, MSH2, PMS2 and MSH6 provide in-
formation of the MMR system functionality. 
IHC analysis with PMS2 and MSH6 antibod-
ies is able to detect most abnormalities in the 
corresponding encoding genes as well as mu-
tations in MLH1 and MSH2; however, IHC 
assay with MLH1/MSH2 antibodies can de-
tect a fraction of MLH1 or MSH2 abnormali-
ties but not all of them. Therefore, IHC anal-
ysis with MSH6 and PMS2 antibodies has 
more diagnostic potential than analysis with 
MLH1 and MSH2 antibodies (Shia, 2008). 
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The main relevance of MSI and IHC is as a 
screening test for Lynch Syndrome. Universal 
MSI/IHC on tumors is increasingly per-
formed throughout the world. 
 
PCR-based method 
For MSI analysis by the fluorescent mul-
tiplex PCR-based method, we need DNA 
from tumor tissues and normal tissues, a se-
ries of primers one of which is fluorescently 
end labeled (the sense strand or antisense 
strand of each primer), a sequencer, and ap-
propriate software. The principle of this 
method is to measure the presence of different 
lengths of specific microsatellite markers in 
tumor cells comparing to normal cells 
(Setaffy and Langner, 2015).  
 
 
 
Figure 1: Mechanism of mismatch repair system: (1) MutSα or MutSβ has recognized the mismatched 
DNA base pairs during replication that the DNA polymerase has matched the mistake base G (guano-
sine) in daughter strand with the T (thymidine) on the template. MutSα or MutSβ can recruit MutLα, 
MutLβ or MutLγ heterodimers by means of exchanging ATP to ADP. This complex (MutS-MutL) creates 
a sliding clamp around the DNA and moves along the new DNA chain when it encounters the DNA 
polymerase complex. (2) The proteins in sliding clamp interact with exonuclease-1 (EXO1) and prolifer-
ating cell nuclear antigen (PCNA). This complex excises the daughter strand back to the site of the 
mismatch. Finally, re-synthesize and re-ligation are performed by DNA polymerase and DNA ligase, 
respectively. The correction occurs (Boland and Goel, 2010). 
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In the first attempt to the diagnosis of MSI 
in CRC, a consensus conference recom-
mended a panel of microsatellite markers in-
cluded three dinucleotide repeats (D5S346, 
D2S123, and D17S250) and 2 mononucleo-
tide repeats (BAT25 and BAT26). Three dis-
tinct MSI phenotypes have been described. If 
two or more microsatellite markers are mu-
tated, the tumor is considered MSI-high 
(MSI-H); if only one is mutated, the tumor is 
defined as MSI-low (MSI-L); and if none of 
the examined loci demonstrate instability, the 
tumor will be considered Microsatellite Sta-
ble (MSS). This panel was known as the Be-
thesda panel (Rodriguez-Bigas et al., 1997). 
A few years later, it was found that mon-
onucleotide markers have a better specificity 
and sensitivity than dinucleotide repeats (di-
nucleotide markers have a polymorphic na-
ture) (Suraweera et al., 2002) and hence Be-
thesda guideline criteria were revised by NCI 
(National Cancer Institute) at the following 
conference in 2004 (Umar et al., 2004). After 
that, the uses of panels containing more mon-
onucleotide markers have been increased due 
to their higher sensitivity and specificity in 
the diagnosis of MSI in CRCs (Table 2) 
(Buhard et al., 2004; Xicola et al., 2007; Goel 
et al., 2010; You et al., 2010; Agostini et al., 
2010; Cicek  et al., 2011). 
 
MSI IN TREATMENT 
The uses of MSI status in the prediction of 
response to adjuvant chemotherapy is contro-
versial although it has been confirmed that 
colorectal tumors displaying MSI have a bet-
ter prognosis compared with MSS tumors. 
Antimetabolites (5-flourouracil), Alkylating 
agents and Topoisomerase Inhibitors are the 
three categories of chemotherapeutic agents 
that are used in CRC treatment (Warusa-
vitarne and Schnitzler, 2007). The chemother-
apeutic treatment is effective in some certain 
patients, but it can cause many adverse ef-
fects, nonetheless (Rothenberg et al., 2001; 
Adlard et al., 2002). MSI-H is one of the po-
tential predictive points to the chemothera-
peutic treatment efficacy and to the level of 
adverse effects in a patient; therefore, several 
clinical trials have been conducted regarding 
this opinion (De la Chapelle and Hampel, 
2010). There are different therapeutic re-
sponses in MSI-H CRCs depending on type of 
adjuvant chemotherapy. When a tumor is to 
be MSI-high, for diagnosis it is either Lynch 
or Methylated. If IHC is done and the unex-
pressed protein is MSH2, PMS2 or MSH6 
then it is Lynch. Germline testing is indicated. 
If the unexpressed protein is MLH1 it could 
be a CIMP tumor with hypermethylation of 
MLH1 promoter, or Lynch. To tell which is 
which, BRAF mutation testing or methylation 
assay on the tumor are helpful. For treatment 
it is a candidate for immune activation ther-
apy if it is advanced. If not advanced it has a 
good prognosis and will not respond to 5 FU 
based therapy. 
 
CONCLUSION AND  
CONCLUDING REMARK 
Since CRC is one of the most prevalent 
cancers in humans and causes a remarkable 
public health problem worldwide, identifying 
the ways of diagnosis and treatment of CRC 
is of most importance. MSI is a significant ge-
netic marker in CRC that can be useful in di-
agnosis, prognosis, and prediction of chemo-
therapeutic treatment efficacy. Nowadays, 
molecular techniques have been developed 
for detection of MSI and drug development 
strategies are focused on specific tumor mo-
lecular characteristics. 
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Table 2: Microsatellite markers used to detect of MSI in CRC 
Marker Associated 
Gene 
MS repeat Chromoso-
mal  
Location 
Primer Sequences Size
(bp) 
Mononucleotide Markers
BAT25 c-kit 25 (T) intron 16 4q12 F:TCGCCTCCAAGAATGTAAGT 
R: TCTGCATTTTAACTATGGCTC 
122–
124 
BAT26 MSH2 26 (A) intron 5 2p21 F: TGACTACTTTTGACTTCAGCC 
R:AACCATTCAACATTTTTAACCC 
116–
117 
NR27 Inhibitor of 
apoptosis 
protein-1 
27(A) 5’UTR 11q22 F: AACCATGCTTGCAAACCACT 
R: CGATAATACTAGCAATGACC 
86–87 
NR21 SLC7A8 21 (T) 5’UTR 14q11 F: TAAATGTATGTCTCCCCTGG 
R: ATTCCTACTCCGCATTCACA 
98–99 
NR22 Transmem-
brane 
precursor 
protein B5 
22 (T)3’UTR 11q24-25 F: GAGGCTTGTCAAGGACATAA 
R: AATTCGGATGCCATCCAGTT 
138–
143 
NR-24 Zinc finger 2 
(ZNF-2) 
24 (T)3’UTR 2q11 F: GCTGAATTTTACCTCCTGAC 
R: ATTGTGCCATTGCATTCCAA 
132 
BAT-RII TGFBR2 (A)n 3p24.1 F: AAGCTCCCCTACCATGACT 
R: TGCACTCATCAGAGCTACAG 
114 
Bat40 3b-HSD (A)n 1p13.1 F: AGTCCATTTTATATCCTCAAGC 
R: GTAGAGCAAGACCACCTTG 
142-
146 
CAT25 Caspase-2 
(CASP2) 
25(T)3’UTR 7q34 F: CCTAGAAACCTTTATCCCTGCTT 
R: GAGCTTGCAGTGAGCTGAGA 
146-
148 
Dinucleotide Markers 
D18S34 DCC CA (n) 18q12.2-
18q12.3 
F: CAGAAAATTCTCTCTGGCTA 
R: CTCATGTTCCTGGCAAGAAT 
103 
D2S123 Linked to 
MSH2 
CA (n) 2p16 F: AAACAGGATGCCTGCCTTTA 
R: GGACTTTCCACCTATGGGAC 
197-
227 
D5S346 Linked to 
APC 
CA (n) 5q22-23 F: ACTCACTCTAGTGATAAATCGGG 
R:AGCAGATAAGACAGTATTACTAGTT 
96 
D17S250 Mfd15A 
 
CA (n) 17q12 F: GGAAGAATCAAATAGACAAT 
R: GCTGGCCATATATATATTTAAACC 
151 
D17S520 --- (CA)n l 7p 1 2 F: GGAGAAAGTGATACAAGGGA 
R: TAGTTAGATTAATACCCACC 
130-
136 
D3S1260 --- (CA)n 3p23-3p21 
3p24.2-3p22 
F: CTACCAGGGAAGCACTGTAG 
R: CATGTACCTGAGCACCTACTG 
185 
D18S69 --- (CA)13TA(CA)15 
(T/GA)7 
18q21 F: CATTAGCAGTCTGGAAATCCTC 
R: CGCTATTGTACTGAAAACCTGA 
193-
210 
D10S197 --- (CA)n 10p12 F: ACCACTGCACTTCAGGTGAC 
R: GTGATACTGTCCTCAGGTCTCC 
161-
173 
D18S58 --- (CA)n 18q22.3 F: GCTCCCGGCTGGTTTT 
R: GCAGGAAATCGCAGGAACTT 
144-
160 
D17S261 Mfd41 (CA)n 17p12–p11.1 F: CAGGTTCTGTCATAGGACTA 
R: TTCTGGAAACCTACTCCTGA 
157–
171 
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